Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Sarcoma 3Genitourinary 3Thoracic 2Dermatologic 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Other 1Gynecologic 1

Conditions

Platinum-resistant Epithelial Ovarian Cancer 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hydroxychloroquine × Gynecologic × Clear all
NCT03081702 2021-04-02

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

University Health Network, Toronto

Phase 1/2 Completed
13 enrolled
Gynecologic

Platinum-resistant Epithelial Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡